Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia
Shimoni, A, Leiba, M, Schleuning, M, Martineau, G, Renaud, M, Koren-Michowitz, M, Ribakovski, E, le Coutre, P, Arnold, R, Guilhot, FVolume:
23
Year:
2008
Language:
english
Pages:
5
DOI:
10.1038/leu.2008.160
File:
PDF, 103 KB
english, 2008